Clinical Data, Inc. (NASDAQ:CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced that it has initiated the second of its two pivotal trials of Vilazodone, the Company’s novel drug candidate for the treatment of depression. This double-blind, placebo-controlled clinical trial is designed to assess the efficacy and safety of Vilazodone.
Popularity: unranked [?]
Related posts:
- Clinical Data Initiates Long-Term Safety Study For Vilazodone
- Clinical Data Initiates Long-Term Safety Study For Vilazodone
- DOV Pharmaceutical, Inc. Initiates Phase II Clinical Trial In Patients With Major Depressive Disorder
- Clinical Data, Inc. Announces Publication Of Results From First Phase III Study Of Vilazodone In Treatment Of Major Depressive Disorder
- Targacept Announces Positive Results Of Phase II Clinical Trial In Major Depression
Comments
No Responses to “Clinical Data, Inc. Initiates Second Pivotal Phase III Study Of Vilazodone”